



Yumi is 72 years old, which puts her at high risk for severe outcomes from COVID-19.¹

“You told me I’m at high risk. Now I’m listening.”

You may think your eligible patients don’t want to talk about COVID-19, but your recommendation matters.²

Actor portrayal.

Age (≥65 years) remains the strongest risk factor for severe outcomes from COVID-19¹

COVID-19 vaccination estimated uptake rates in adults ≥65 years^{3*}

From September 1, 2025-January 17, 2026

~34%
of individuals ≥65 years were estimated to have received a 2025-2026 formula COVID-19 vaccine.



~2 of 3 older individuals remain unvaccinated,*

leaving many patients ≥65 years at high risk for severe COVID-19 outcomes.

*Based on the National Immunization Surveys-Fall Respiratory Virus Module (NIS-FRVM). 33.8% of adults ≥65 years were estimated to have received at least one 2025-2026 COVID-19 vaccine dose since September 1, 2025. Data as of January 17, 2026.³

Your COVID-19 vaccination recommendation matters.²



~8 out of 10 patients ≥65 years reported that they would **accept a COVID-19 vaccination** based on a healthcare professional’s recommendation.⁴

INDICATION and IMPORTANT SAFETY INFORMATION for COMIRNATY

INDICATION

COMIRNATY is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

COMIRNATY is approved for use in individuals who are:

- 65 years of age and older, or
- 5 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

IMPORTANT SAFETY INFORMATION

Do not administer COMIRNATY[®] (COVID-19 Vaccine, mRNA) to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of COMIRNATY or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Pfizer-BioNTech COVID-19 vaccine.

Management of Acute Allergic Reactions

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of COMIRNATY.

Please see next page for additional COMIRNATY Important Safety Information.

Please click for [COMIRNATY Full Prescribing Information](#) and [Patient Information](#).

~5 years of clinical experience^{5*}

COMIRNATY has been the most administered COVID-19 vaccine in individuals ≥65 years⁶⁻⁸



~152 million doses[†]
administered to individuals ≥65 years⁶⁻⁸

*Initial US approval in 2021.⁵

†Inclusive of US-administered vaccine doses from formulas encoding the SARS-CoV-2 spike protein for Wuhan-Hu-1 strain (Original), Omicron BA.4/BA.5, Omicron XBB.1.5, Omicron JN.1, Omicron KP.2, and Omicron LP.8.1. Data are for individuals ≥65 years from 2020 to December 2025, and are reflective of deductions for returned vaccine doses.⁶⁻⁸



COMIRNATY prefilled syringes have a shelf life of up to 12 months from date of manufacture when stored refrigerated at 2°C to 8°C (35°F to 46°F). **DO NOT FREEZE.**^{5,9}

Help protect eligible individuals with COMIRNATY.⁵

Learn more at
COMIRNATYHCP.com

IMPORTANT SAFETY INFORMATION (Cont'd)

Myocarditis and Pericarditis

Postmarketing data from use of authorized or approved mRNA COVID-19 vaccines, including COMIRNATY, have demonstrated increased risks of myocarditis and pericarditis, with onset of symptoms typically in the first week following vaccination. The observed risk has been highest in males 12 years through 24 years of age.

Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines, including COMIRNATY. Procedures should be in place to avoid injury from fainting.

Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to COMIRNATY.

Limitation of Vaccine Effectiveness

COMIRNATY may not protect all vaccine recipients.

Adverse Reactions

Most commonly reported adverse reactions after a dose:

- **12 years of age and older (≥10%)** were pain at the injection site (up to 90.5%), fatigue (up to 77.5%), headache (up to 75.5%), chills (up to 49.2%), muscle pain (up to 45.5%), joint pain (up to 27.5%), fever (up to 24.3%), injection site swelling (up to 11.8%), and injection site redness (up to 10.4%).
- **5 years through 11 years of age (≥5%)** were pain at the injection site (up to 83.8%), fatigue (up to 51.9%), headache (up to 38.4%), injection site redness (up to 25.9%), injection site swelling (up to 20%), muscle pain (up to 18.1%), chills (up to 13.3%), fever (up to 7.8%), and joint pain (up to 7.6%).

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or <https://www.pfizersafetyreporting.com> or VAERS at 1-800-822-7967 or <https://vaers.hhs.gov>

Please see previous page for additional COMIRNATY Important Safety Information.

Please click for [COMIRNATY Full Prescribing Information and Patient Information](#).

SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.

References: 1. Underlying conditions and the higher risk for severe COVID-19. Centers for Disease Control and Prevention. Updated February 6, 2025. Accessed February 10, 2026. <https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html> 2. For health care providers. US Department of Health and Human Services. Updated February 20, 2025. Accessed February 10, 2026. <https://www.hhs.gov/risk-less-do-more/for-health-care-providers/index.html> 3. COVID-19 vaccination coverage and intent for vaccination, adults 18 years and older, United States. Centers for Disease Control and Prevention. Updated January 17, 2026. Accessed January 30, 2026. <https://www.cdc.gov/covidvaxview/weekly-dashboard/adult-vaccination-coverage.html> 4. Data on file. BioNTech Manufacturing GmbH and Pfizer Inc.; May 23, 2025. 5. COMIRNATY® (COVID-19 Vaccine, mRNA). Prescribing Information. BioNTech Manufacturing GmbH and Pfizer Inc.; August 27, 2025. 6. COVID-19 vaccinations in the United States, jurisdiction. Centers for Disease Control and Prevention. Updated May 12, 2023. Accessed February 10, 2026. https://data.cdc.gov/Vaccinations/COVID-19-Vaccinations-in-the-United-States-Jurisdiction/uns-k-b7fc/about_data 7. IQVIA National Prescription Audit, retail (September 2023-December 2025). 8. IQVIA National Prescription Audit and Drug Distribution Data (September 2023-December 2025). 9. Data on file. BioNTech Manufacturing GmbH and Pfizer Inc.; April 18, 2025.



Manufactured for
BioNTech Manufacturing GmbH
An der Goldgrube 12
55131 Mainz, Germany
Marketing Authorization Holder

Manufactured by
Pfizer Inc.
New York, NY 10001

COMIRNATY[®]
(COVID-19 Vaccine, mRNA)

The formulation of COMIRNATY, which is based on BioNTech proprietary mRNA technology, was developed by BioNTech and Pfizer.

© 2026 Pfizer Inc. All rights reserved.
PP-CVV-USA-5694 March 2026